Pharmacia takes a shot at sepsis
Executive Summary
"You will be hearing more...in the fall" about the potential sepsis agent tifacogin, Pharmacia CFO Chris Coughlin tells the Goldman Sachs conference June 14. "It is a high risk area" and "we tend to be conservative and not try to tout these things too early," Coughlin says. The recombinant protein tissue factor pathway inhibitor, being developed in collaboration with Chiron, entered Phase III in mid-2000; interim data from the two-year, 1,500-patient trial will be analyzed around year-end (1"The Pink Sheet" Feb. 14, 2000, p. 33)